Literature DB >> 7877394

Abnormal uterine bleeding.

P I Wathen1, M C Henderson, C A Witz.   

Abstract

Concerns about abnormal menstrual bleeding are a common reason for women to consult a primary care physician. The first step in the evaluation is to determine the patient's ovulatory status. Women with heavy bleeding but normal ovulatory cycles should be evaluated for coagulopathies, structural lesions, and hypothyroidism. In the absence of a systemic or structural cause, menorrhagia can be treated with OCPs or NSAIDs. Intermenstrual bleeding in OCP users may be due to noncompliance or the use of low-dose pills. Encouraging patient compliance and adjustment of the estrogen dose can often solve the problem. If the patient is not on OCPs, intermenstrual bleeding is usually due to a structural or inflammatory lesion. The differential diagnosis for anovulatory bleeding is extensive. Pregnancy, systemic illnesses, and structural lesions should be ruled out by history, physical examination, and laboratory evaluation. Endometrial biopsy is indicated in patients over age 35 and younger patients with risk factors for endometrial cancer, such as chronic anovulation and obesity. Dysfunctional uterine bleeding is a nonspecific term for abnormal uterine bleeding in the absence of systemic or structural disease. It is usually associated with anovulation. Adolescents frequently have dysfunctional uterine bleeding owing to immaturity of the hypothalamic-pituitary-ovarian axis. Perimenopausal women have an increased incidence of irregular bleeding secondary to decreased estrogen production by the ovary. Obesity, polycystic ovary syndrome, stress, crash diets, and vigorous exercise can all disrupt normal ovulatory function. Treatment options for dysfunctional uterine bleeding include oral contraceptives, cyclic progesterone, or hormone replacement with estrogen and progesterone. Patients with structural lesions or those who do not resume normal withdrawal bleeding patterns on hormone therapy should be referred to a gynecologist for further evaluation and treatment.

Entities:  

Mesh:

Year:  1995        PMID: 7877394     DOI: 10.1016/s0025-7125(16)30071-2

Source DB:  PubMed          Journal:  Med Clin North Am        ISSN: 0025-7125            Impact factor:   5.456


  3 in total

1.  Detection of ebaf, a novel human gene of the transforming growth factor beta superfamily association of gene expression with endometrial bleeding.

Authors:  R Kothapalli; I Buyuksal; S Q Wu; N Chegini; S Tabibzadeh
Journal:  J Clin Invest       Date:  1997-05-15       Impact factor: 14.808

2.  Menstrual function among women exposed to polybrominated biphenyls: a follow-up prevalence study.

Authors:  Stephanie I Davis; Heidi Michels Blanck; Vicki S Hertzberg; Paige E Tolbert; Carol Rubin; Lorraine L Cameron; Alden K Henderson; Michele Marcus
Journal:  Environ Health       Date:  2005-08-09       Impact factor: 5.984

3.  Menstrual changes following COVID-19 infection: A cross-sectional study from Jordan and Iraq.

Authors:  Mohammad A A Al-Najjar; Ruaa R Al-Alwany; Firas M Al-Rshoud; Rana K Abu-Farha; Mohammed Zawiah
Journal:  PLoS One       Date:  2022-06-29       Impact factor: 3.752

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.